Developer docs
API playgroundTry for free, no card

Search company profiles

Acelity

Full company profile

uuid0007g7p

Namestring
Acelity
Legal namestring
Acelity L.P. Inc.
Websiteurl
acelity.com
Company typeenum
Private
Founded yearint
1976
Descriptiontext

Acelity is a global advanced wound care company founded in 1976 and headquartered in San Antonio, Texas, with a workforce of 1,001–5,000 employees. The company develops and commercializes advanced wound healing technologies spanning negative pressure wound therapy (NPWT), wound care biologics and regenerative medicine, smart bandages with real-time monitoring capabilities, and needle-free injection delivery systems. Its products target chronic wounds, diabetic foot ulcers, burn injuries, pressure ulcers, and surgical site complications, serving healthcare providers including hospitals, wound care centers, and specialty clinics treating patients with diabetes, obesity-related comorbidities, and age-related wound care needs. Acelity employs a horizontal segmentation approach across use cases rather than vertical specialization, with technology differentiators in domain specialization, novel method architecture, and integration/interoperability.

The company was acquired by Solventum — then operating as 3M's healthcare division — in 2019, and following 3M's 2024 spin-off of Solventum, Acelity's operations now sit within Solventum's Medical Solutions segment alongside surgical solutions, IV site management, sterilization assurance, patient monitoring, and oral care franchises. Acelity competes in multiple high-growth wound care markets: the diabetic foot ulcer treatment market (USD 5.51 billion in 2024, 7.45% CAGR to 2030) and the broader chronic wound care market (USD 7.04 billion in 2025 to USD 20.64 billion by 2033 at 14.39% CAGR), alongside 3M, Medtronic, Smith & Nephew, ConvaTec, Coloplast, B Braun, Medline, and Organogenesis. Pricing, detailed go-to-market mechanics, and standalone revenue figures are not disclosed in available sources.

The 2018 acquisition of Crawford Healthcare Ltd. expanded Acelity's advanced wound and skin care portfolio ahead of its own sale, while subsequent product-line moves into smart bandages and needle-free injection systems signaled platform expansion into digitally enabled and adjacent drug-delivery categories. Post-spin, the strategic significance of Acelity within Solventum depends on portfolio prioritization across the parent company's medical franchises.

Short descriptiontext

Acelity is a global advanced wound care company developing NPWT, wound care biologics, smart bandages with real-time monitoring, and needle-free injection systems for hospitals, wound care centers, and specialty clinics treating chronic wounds, diabetic foot ulcers, burns, and pressure ulcers.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSan Antonio, United States
HQ citystring
San Antonio
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
advanced wound care, negative pressure wound therapy, wound care biologics, smart bandages, diabetic foot ulcer treatment
Industry5 codes
1Negative Pressure Wound Therapy (NPWT) Systems & Accessories
CodeHLAHALABPrimaryYes
2Wound Care & Ulcer Management
CodeHLAKACANPrimaryNo
3Wound Care & Diabetic Foot Infection
CodeHLAKAGAKPrimaryNo
4Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
CodeHLAHALAEPrimaryNo
5First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care)
CodeCRADAMABPrimaryNo
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Advanced Wound Care
Social media profiles2 records
Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Acelity is a global advanced wound care company that develops and markets advanced wound healing technologies, including negative pressure wound therapy (NPWT), wound care biologics, and smart bandage innovations for chronic wound management, diabetic foot ulcers, burns, and surgical site care.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Global diabetic foot ulcer treatment market projected to grow from USD 5.51 billion in 2024 to USD 8.48 billion by 2030 at 7.45% CAGR
+2 more records
Product and service3 records
1Smart Bandages Technology
CategorySmart Bandages
Description

Advanced wound monitoring and management technologies incorporating real-time monitoring capabilities for healthcare providers treating complex wounds.

2Wound Care Biologics
CategoryWound Care Biologics
Description

Advanced wound care and regenerative medicine technologies for chronic wound management including diabetic foot ulcers and burns.

3Needle-Free Injection Systems
CategoryDrug Delivery Systems
Description

Technologies for needle-free injection delivery systems used in clinical and therapeutic applications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acelity

Advanced Wound Careacelity.com

Acelity is a global advanced wound care company developing NPWT, wound care biologics, smart bandages with real-time monitoring, and needle-free injection systems for hospitals, wound care centers, and specialty clinics treating chronic wounds, diabetic foot ulcers, burns, and pressure ulcers.

What Acelity does

Acelity is a global advanced wound care company founded in 1976 and headquartered in San Antonio, Texas, with a workforce of 1,001–5,000 employees. The company develops and commercializes advanced wound healing technologies spanning negative pressure wound therapy (NPWT), wound care biologics and regenerative medicine, smart bandages with real-time monitoring capabilities, and needle-free injection delivery systems. Its products target chronic wounds, diabetic foot ulcers, burn injuries, pressure ulcers, and surgical site complications, serving healthcare providers including hospitals, wound care centers, and specialty clinics treating patients with diabetes, obesity-related comorbidities, and age-related wound care needs. Acelity employs a horizontal segmentation approach across use cases rather than vertical specialization, with technology differentiators in domain specialization, novel method architecture, and integration/interoperability.

The company was acquired by Solventum — then operating as 3M's healthcare division — in 2019, and following 3M's 2024 spin-off of Solventum, Acelity's operations now sit within Solventum's Medical Solutions segment alongside surgical solutions, IV site management, sterilization assurance, patient monitoring, and oral care franchises. Acelity competes in multiple high-growth wound care markets: the diabetic foot ulcer treatment market (USD 5.51 billion in 2024, 7.45% CAGR to 2030) and the broader chronic wound care market (USD 7.04 billion in 2025 to USD 20.64 billion by 2033 at 14.39% CAGR), alongside 3M, Medtronic, Smith & Nephew, ConvaTec, Coloplast, B Braun, Medline, and Organogenesis. Pricing, detailed go-to-market mechanics, and standalone revenue figures are not disclosed in available sources.

The 2018 acquisition of Crawford Healthcare Ltd. expanded Acelity's advanced wound and skin care portfolio ahead of its own sale, while subsequent product-line moves into smart bandages and needle-free injection systems signaled platform expansion into digitally enabled and adjacent drug-delivery categories. Post-spin, the strategic significance of Acelity within Solventum depends on portfolio prioritization across the parent company's medical franchises.

Acelity firmographics

Firmographics
Name
Acelity
Legal name
Acelity L.P. Inc.
Website
https://acelity.com
Company type
Private
Founded year
1976
Operating status
Acquired
Headcount range
1,001–5,000 employees
Short description
Acelity is a global advanced wound care company developing NPWT, wound care biologics, smart bandages with real-time monitoring, and needle-free injection systems for hospitals, wound care centers, and specialty clinics treating chronic wounds, diabetic foot ulcers, burns, and pressure ulcers.
Ownership category
akta.pro rank

Acelity industry classification

Industry
Product category
Advanced Wound Care
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro primary industry
Negative Pressure Wound Therapy (NPWT) Systems & Accessories (HLAHALAB)
akta.pro secondary industries
Wound Care & Ulcer Management (HLAKACAN), Wound Care & Diabetic Foot Infection (HLAKAGAK), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care) (CRADAMAB)

Keywords

  • Advanced wound care
  • Negative pressure wound therapy
  • Wound care biologics
  • Smart bandages
  • Diabetic foot ulcer treatment

Where Acelity is headquartered

Location

Headquarters

HQ city
San Antonio
HQ country
United States
HQ region
North America

Markets served

Acelity business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Acelity product offering

Product offering

Core offering

Acelity is a global advanced wound care company that develops and markets advanced wound healing technologies, including negative pressure wound therapy (NPWT), wound care biologics, and smart bandage innovations for chronic wound management, diabetic foot ulcers, burns, and surgical site care.

Differentiator

Problem solved

Functional benefit

Products and services

  • Smart Bandages Technology Advanced wound monitoring and management technologies incorporating real-time monitoring capabilities for healthcare providers treating complex wounds.
  • Wound Care Biologics Advanced wound care and regenerative medicine technologies for chronic wound management including diabetic foot ulcers and burns.
  • Needle-Free Injection Systems Technologies for needle-free injection delivery systems used in clinical and therapeutic applications.

Quantifiable outcome

  • Global diabetic foot ulcer treatment market projected to grow from USD 5.51 billion in 2024 to USD 8.48 billion by 2030 at 7.45% CAGR
  • +2 more outcomes

Companies that use Acelity

Customer profile

Segments2 records

Ideal customer profiles1 record

Acelity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Acelity partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Acelity competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat3 records

Customer concentration

Acelity social profiles

Digital presence

Acelity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acelity leadership team

Management profile

Number of profiles

Profiles4 records

Acelity funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acelity M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acelity

What does Acelity do?

Acelity is a global advanced wound care company that develops and markets advanced wound healing technologies, including negative pressure wound therapy (NPWT), wound care biologics, and smart bandage innovations for chronic wound management, diabetic foot ulcers, burns, and surgical site care.

When was Acelity founded?

Acelity was founded in 1976. It employs 1,001 to 5,000 people.

Where is Acelity based?

Acelity is headquartered in San Antonio, United States, in the North America region.

Does Acelity have an API?

No public API is recorded for Acelity.

What industry is Acelity in?

Acelity's product category is Advanced Wound Care. Its primary akta.pro industry code is HLAHALAB, Negative Pressure Wound Therapy (NPWT) Systems & Accessories, with a secondary code of HLAKACAN, Wound Care & Ulcer Management. Its NAICS code is 541714 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireWound Care Market to reach USD 47.13 Billion by 2035 at 6.45% CAGRThe global wound care market is projected to grow from USD 25.22 billion in 2025 to USD 47.13 billion by 2035, a CAGR of 6.45%. Growth is driven by rising chronic diseases, technological innovations, and an aging population, with North America leading at over 42% of global revenue.openPR.comNeedle Free Injection Systems Market Is Going to Boom Rapidly With Top Key Players InsuJet • Acelity • Valeritas • InjexThe article discusses the rapid growth forecast for the needle free injection systems market from 2026 to 2033, emphasizing key companies involved in the industry. It highlights market trends, drivers, challenges, and strategic insights for industry stakeholders.openPR.comGlobal Wound Care Management Market Size, Growth, Trends & Forecast to 2033 Acelity, Smith & Nephew, MedtronicFuture Market Report has published a market research study on the Global Wound Care Management Market, covering demand and forecasts from 2024 to 2032. The report analyzes key industry players including Acelity, Smith & Nephew, and Medtronic, along with market segmentation by product type, end-user, and region. It provides strategic insights into revenue, gross margins, and competitive dynamics within the wound care sector.YahooDiabetic Foot Ulcer Treatment Market Trends and Forecasts, 2020-2024 & 2025-2030 Featuring 3M, Medtronic, ConvaTec, Coloplast, Smith & Nephew, B Braun, Medline, Organogenesis, Molnlycke, AcelityThe global diabetic foot ulcer treatment market was valued at USD 5.51 billion in 2024 and is projected to reach USD 8.48 billion by 2030, growing at a CAGR of 7.45%. Key drivers include rising diabetes prevalence (affecting 537 million adults worldwide in 2021, projected to reach 783 million by 2045), sedentary lifestyles, aging populations, and increasing obesity rates. The report identifies telemedicine integration and remote wound monitoring as emerging trends, while highlighting high treatment costs and limited reimbursement in developing regions as key challenges constraining market growth.PR NewswireGlobal Medtech Mergers and Acquisitions (M&As) Analysis Report 2021: Robotic Surgical Innovations Witness a Huge Surge & Increased Acquisitions to Enhance Connected Care CapabilitiesResearchAndMarkets.com released a comprehensive report examining global medtech mergers and acquisitions trends driven by COVID-19 pandemic adaptations and technological evolution. The report analyzes how companies pursued M&A to acquire new capabilities in areas like robotic surgery, connected care, and digital health solutions, while also documenting divestitures made to reduce debt or focus on organic growth. Key deals profiled include Baxter's acquisition of Hill-Rom, Siemens Healthineers' acquisition of Varian Medical, STERIS's acquisition of Cantel, and 3M's acquisition of Acelity.PR NewswireTissue Engineered - Skin Substitutes (Wound Care Management) - Global Market Analysis and Forecast Model (COVID-19 market impact)Reportlinker has published a market analysis and forecast model for the Tissue Engineered - Skin Substitutes market within the Wound Care Management sector, covering the impact of COVID-19 on the market for 2020 and beyond. The report identifies chronic wound treatment costs in the United States at approximately $32 billion annually, with 90% of chronic wounds resulting from diabetes, venous stasis, radiation, or paralysis. The market model covers 39 countries with epidemiology-based indications, procedure volumes, and competitive landscape analysis for key industry players including Integra LifeSciences Corp, LifeNet Health Inc, MiMedx Group Inc, Organogenesis Inc, Acelity Holdings Inc, and Molnlycke Health Care AB.GlobeNewswireThe Global Wound Biologics Market is expected to grow from USD 3,423.12 Million in 2018 to USD 6,712.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 10.09%The global wound biologics market is projected to grow from USD 3,423.12 million in 2018 to USD 6,712.12 million by 2025, a CAGR of 10.09%. The report covers vendors such as Acelity, Avita Medical, and ConvaTec, and segments the market by product and geography.GlobeNewswireThe Global Wound Biologics Market is expected to grow from USD 3,423.12 Million in 2018 to USD 6,712.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 10.09%The global wound biologics market is projected to grow from USD 3,423.12 million in 2018 to USD 6,712.12 million by 2025, a CAGR of 10.09%. The report covers vendors such as Acelity, Avita Medical, and ConvaTec, and segments the market by product and geography.PR NewswireGlobal $11 Billion Advanced Wound Care Markets, 2016-2019 & 2019-2024ResearchAndMarkets has published a report forecasting the global advanced wound care market to reach $11.06 billion by 2024, driven by an aging population and rising chronic wound incidences. The report highlights that North America holds the largest market share while Asia-Pacific is expected to grow fastest, with significant industry consolidation anticipated following 3M's acquisition of Acelity.PR NewswireGlobal Wound Care Solutions Market Report 2019-2025ResearchAndMarkets has published a market report forecasting the Global Wound Care Solutions Market to grow at a CAGR of approximately 5.0% through 2025, driven by rising diabetes prevalence and technological advancements. The report highlights that North America held the largest market share in 2018, while the Asia Pacific region is expected to see the fastest growth due to increasing healthcare expenditure. A key strategic development noted is 3M's acquisition of Acelity L.P. Inc., which aims to strengthen its position in advanced wound care solutions.